# A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)

> **NCT03224182** · PHASE3 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 118 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Qapzola
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03224182
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-04
- **Primary completion:** 2019-09-26
- **Final completion:** 2019-09-26
- **Target enrollment:** 118 (ACTUAL)
- **Why stopped:** Suspended development
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03224182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03224182, "A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03224182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*